Related Experiment Video

Updated: May 17, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Apigenin Modulates Insulin-like Growth Factor Axis: Implications for Prevention and Therapy of Prostate Cancer

Melissa A Babcook1, Sanjay Gupta

  • 1The Urology Institute; University Hospitals Case Medical Center; 10900 Euclid Avenue; Cleveland, Ohio 44106, USA. sanjay.gupta@case.edu.

Current Drug Targets
|November 13, 2012
PubMed

Insights

Apigenin, a natural compound, shows promise in preventing prostate cancer by targeting the insulin-like growth factor (IGF) axis. Further human studies are warranted to confirm its effectiveness in cancer chemoprevention.

Area of Science:

  • Oncology
  • Molecular Biology
  • Nutritional Science

Background:

  • Aberrant insulin-like growth factor (IGF) axis signaling is implicated in prostate cancer development, progression, and metastasis.
  • Targeting the IGF axis offers a potential strategy for prostate cancer chemoprevention and chemotherapy.
  • Apigenin, a dietary flavone, has demonstrated the ability to modulate the IGF axis.

Purpose of the Study:

  • To evaluate apigenin's potential in correcting IGF axis abnormalities relevant to prostate cancer.
  • To assess apigenin's efficacy in inducing growth arrest and apoptosis in prostate cancer models.
  • To establish apigenin as a candidate for human pilot studies in prostate cancer prevention.

Main Methods:

  • Pre-clinical in vitro and in vivo studies were conducted using prostate cancer models.
  • Apigenin's effects on the IGF axis were investigated.
  • Apigenin's capacity to induce growth arrest and apoptosis was assessed.

Main Results:

  • Apigenin effectively modulated the IGF axis in pre-clinical models.
  • Apigenin demonstrated efficacy in inducing growth arrest and apoptosis in prostate cancer cells.
  • Apigenin exhibited effectiveness at physiologically relevant levels in animal models.

Conclusions:

  • Apigenin corrects IGF axis abnormalities implicated in prostate cancer.
  • Apigenin shows potential as a chemopreventive and/or chemotherapeutic agent for prostate cancer.
  • Apigenin is a strong candidate for human pilot studies on prostate cancer prevention and progression.

More Related Videos

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...